In osteoblast-enriched cultures from fetal rat bone, the A-chain homodimer of platelet-derived growth factor (PDGF-AA) is less potent than the PDGF isoforms containing B chain subunits (PDGF-AB and PDGF-BB), but normal osteoblasts appear to synthesize only PDGF-A subunit mRNA and polypeptide. However, other agents may regulate PDGF-AA activity in skeletal tissue. Pretreatment of osteoblast-enriched cultures with interleukin la (IL-la) or tumor necrosis factor-a (TNF-a) synergistically enhanced the mitogenic effect of PDGF-AA coincident with increased binding site occupancy, but neither factor augmented PDGF-BB activity or binding. Polyacrylamide gel analysis showed 15I-PDGF-AA binding complexes predominantly at > 200 kD and faint labeling at 185 kD. After IL-la or TNF-a pretreatment, PDGF-AA binding increased at both sites, but this effect was more striking at 185 kD, which co-migrated with 125I-PDGF-BB-labeled complexes. PDGF-AA binding sites were rapidly lost by comparison to those for PDGF-BB in cycloheximide-treated cultures, but they remained relatively enhanced by IL-la and TNF-a pretreatment. These studies indicate that IL-a and TNF-a increase PDGF-AA binding and activity for osteoblasts by mechanisms that are at least in part independent of new receptor synthesis, and suggest regulatory events that could control how PDGF binding sites specifically recognize different ligands. (J. Clin. Invest.
1. Abbreviations used in this paper: BS3, bis(sulfosuccinimidyl) suberate; DSS, disuccinimidyl suberate; PDGF, platelet-derived growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor. duced in a variety of tissues where it acts as a local mitogen (1) (2) (3) (4) (5) (6) . In many tissue systems, including osteoblast-enriched cultures from fetal rat bone, the biochemical effects of each dimer (PDGF-AA, PDGF-AB, PDGF-BB) are graded with regard to PDGF-B subunit content, with PDGF-BB being the most stimulatory (7-1 1) . This occurs at least in part by (a) the existence of two binding sites, termed PDGF-a and PDGF-(3 receptor subunits, (b) inefficient binding by PDGF-AA to ,B receptor subunits, and (c) the likelihood that ( receptor subunit occupancy permits optimal PDGF-mediated biological effects (8, (10) (11) (12) (13) (14) (15) .
In some cell systems, notably cultured murine fibroblasts, preexposure to PDGF enhances the mitogenic effect ofcertain so-called progression factors (16, 17) . In osteoblast-enriched cultures from fetal rat bone, PDGF isoforms containing B subunits (PDGF-BB and PDGF-AB) induce potent increases in cell replication without the addition ofother agents (1 1, 18) . In addition, several lines of evidence suggest that normal osteoblasts produce only PDGF-A subunit transcripts and polypeptide (6, 19 ), but exhibit a limited response to PDGF-AA (1 1). Consequently, osteoblasts might require a second agent, produced by cells beyond their lineage, in order to increase the effectiveness of PDGF-AA in bone. Macrophages are prominent at the sites of inflammation after fracture and during the "reversal" phase of remodeling before new bone formation (20) . Activated macrophages store and release a number of growth regulators (21) (22) (23) (24) , and these agents could be involved in the local control ofosteoblast activity. Among the well-described macrophage products are interleukin la (IL-la), tumor necrosis factor-a (TNF-a), and transforming growth factor-,B (TGF-,B) (22) (23) (24) . Of these, TGF-# induces potent effects on replication and differentiated function in a variety of in vitro and in vivo models used to study bone metabolism (25) (26) (27) (28) (29) . IL-la and TNF-a also regulate a number ofbiochemical processes involved in bone remodeling in intact bone organ cultures (30) (31) (32) (33) . By themselves, IL-la and TNF-a induce limited effects in osteoblast-enriched cultures from fetal rat bone (34, 35) , suggesting that some activities regulated by these agents in the intact tissue could result from interactions with other factors produced locally in bone. In this regard, an interdependency between IL-la or TNF-a and PDGF-AA, by way of alterations in IL-la binding or PDGF-AA synthesis, has been reported previously in other tissue systems (4, 36, 37) .
The present studies were therefore performed to assess the possibility that the modest activity of PDGF-AA in bone cell cultures could be enhanced by macrophage-derived products, and to determine if these factors could do so by modifying PDGF-AA receptor binding. Regulatory effects of these sorts could be important to increase in a selective manner the anabolic function of locally produced PDGF-AA during fracture repair or normal bone remodeling.
Methods
Cell cultures. Parietal bones from 22- 
Results
Comparable to earlier studies (1 1), after 23 h oftreatment with PDGF-AA at 0.3-3 nM, DNA synthesis rates were enhanced two-to threefold in serum-deprived osteoblast-enriched cultures from fetal rat parietal bone. The effect of PDGF-AA was near-maximal at 1-3 nM, whereas PDGF-BB at 0.1-3 nM increased DNA synthesis rates two-to eightfold. When the cultures were exposed to IL-la at 0.6-6 nM for the 20-h serum deprivation interval and then supplemented with control medium, only a marginal 0.4-fold increase in the basal rate of DNA synthesis was achieved. However, ifthe IL-la-pretreated cultures were subsequently supplemented with PDGF-AA, there was a synergistic increase in DNA synthesis to essentially the level produced by PDGF-BB alone. The effect was dose dependent with regard to IL-la, inducing PDGF-BB-like increases at -6 nM. Parallel studies with PDGF-BB did not reveal a corresponding synergy between any concentrations of IL-la or PDGF-BB examined (Fig. 1) . Similarly, IL-la pretreatment enhanced total DNA content in cultures supplemented with PDGF-AA, but did not modify the amount of DNA produced in cultures treated with PDGF-BB (Table I) .
Analogous studies were performed after TNF-a pretreatment. Earlier work in this culture model demonstrated that, relative to several other growth regulators, TNF-a by itselfproduces only moderate increases in DNA synthesis rates (34, 42) , and its effect was somewhat less pronounced (-2.5-fold) after the additional 23-h culture interval used in the present studies. Nevertheless, similar to IL-la, pretreatment with TNF-a at 0.6-6 nM specifically enhanced the mitogenic effect of PDGF-AA. Synergy was observed between 0.3 nM PDGF-AA and 0.6-6 nM TNF-a, but the combined effects of 0.3 nM PDGF-BB and TNF-a were less than additive (Table II, experiment 1). Even at a PDGF-AA concentration of 1 nM, which is nearmaximal in unpretreated cultures, its effectiveness was increased synergistically in TNF-a-pretreated cultures, whereas the stimulatory effect of 1 nM PDGF-BB was inhibited by TNF-a pretreatment (Table II, experiment 2) .
In contrast to results with IL-1 a and TNF-a, pretreatment of the osteoblast-enriched cultures with TGF-# 1 did not produce analogous changes in the mitogenic effects of PDGF-AA or PDGF-BB (Table II, DNA synthesis was measured by pulse-labeling with [3H]thymidine for the last 2 h of culture as described in Methods. Data are shown as dpm x 10-4/culture, and are given as mean±SE of four replicate 0.32-cm2 culture wells per condition. Similar results were obtained in three separate experiments. In the absence ofIL-la, PDGF-AA at 3 nM or PDGF-BB at 0.3-3 nM significantly enhanced DNA synthesis (P < 0.05). The combined effect of pretreatment with 6 nM IL-a and treatment with 0.3-3 nM PDGF-AA, but not PDGF-BB, was significantly different from that by either factor alone (P < 0.01).
to PDGF-AA could have resulted from a differential increase in its binding capacity. This was examined by measuring PDGF-AA and PDGF-BB binding after pretreatment with ILla or TNF-a. Increases in PDGF-AA binding were detected within 4 h of pretreatment with either factor and continued to (Table III) . The effects of IL-la and TNF-a were each dose-related (Table IV) . Scatchard analysis indicated that a 24-h pretreatment with IL-la (Fig. 2 ) or TNF-a (not shown) produced a nearly twofold increase in PDGF-AA binding capacity without altering its affinity, but neither IL-la nor TNFa significantly altered PDGF-BB binding (Fig. 2 and Tables III  and IV) . Furthermore, the stimulatory effects of IL-la and TNF-a were not universal, since pretreatment with TGF-f13 specifically decreased PDGF-AA binding without altering PDGF-BB binding in these cultures (Fig. 3 and Table IV ). Although there was some variability in the calculated amounts of either PDGF-AA or PDGF-BB binding using different batches of radiolabeled ligand, the relative effects of pretreatment with various agents were consistent throughout the course of these studies.
When the cultures were incubated with either '25I-PDGF-AA or 125I-PDGF-BB, chemically cross-linked, and examined by polyacrylamide gel electrophoresis and autoradiography, different binding profiles were obtained with each radioligand (Fig. 4) . Even though its banding pattern was somewhat indistinct, complexes containing 125I-PDGF-AA migrated predominantly at > 200 kD, with a small degree of binding at 185 kD (lane 1). In contrast, '23I-PDGF-BB labeled complexes migrated predominantly at 185 kD (lane 2). Analogous to previously reported cross-competition binding studies in these cultures (1 1), unlabeled PDGF-AA reduced 1251-PDGF-AA binding at these sites and only moderately decreased that by 125I-PDGF-BB (lanes 9 and 10), whereas unlabeled PDGF-BB blocked binding by both radioligands (lanes 6 and 7). Binding profiles obtained from cultures pretreated with ILla demonstrated an increase in 1251I-PDGF-AA binding at both binding sites (> 200 and 185 kD), but there was a relatively greater increase in its association within the complexes found at 185 kD (Fig. 4, lane 3) . Consistent with the data obtained from saturation binding studies, IL-a did not alter '25I-PDGF-BB binding at either location (Fig. 4, lane 4) . 1251-PDGF-AA was convincingly displaced by unlabeled PDGF-AA in both control and IL-Ia pretreated cultures (Fig. 5, lanes 2 and 5) , whereas unlabeled PDGF-BB competed less well for 125[-PDGF-AA binding after IL-la pretreatment (Fig. 5, lanes 3  and 6) . Furthermore, consistent with total PDGF-BB binding and cross-linking studies, competition by unlabeled PDGF-AA or PDGF-BB for '25I-PDGF-BB binding was not different in either situation (not shown). Similar increases in '251-PDGF-AA binding occurred after TNF-a pretreatment (Fig. 6, lane 2) , while TGF-13I pretreatment completely reduced 1251-PDGF-AA binding throughout the polyacrylamide gel profile (Fig. 6 , Isoform-specific Platelet-derived Growth Factor Activity and Binding 1079 Fig. 2 AA binding relative to that in cycloheximide-treated cultures, whereas decreases in PDGF-BB binding were approximately equivalent after treatment with either inhibitor. IL-la also enhanced PDGF-AA binding in a-amanitin-treated cultures above the levels observed with the toxin alone, but did not augment PDGF-BB binding in either situation (Fig. 8 and Table 6). Similar results were obtained in cultures pretreated with either IL-la or TNF-a and each metabolic inhibitor (Table VI).
Discussion
Earlier work in several model systems, including osteoblastenriched cultures from fetal rat bone, revealed that the maximal mitogenic potency of PDGF-AA, PDGF-AB, and PDGF-BB depends on the presence of PDGF-B subunits (4, 7-1 1). In some cultures this effect appears to result from the existence of independent PDGF-a and PDGF-# receptor subunits that dimerize in response to ligand binding, and the different affinities of each receptor subunit for the individual ligand subunit chains (14) . Although PDGF-a receptor subunits bind either PDGF-A or PDGF-B chains (and therefore all dimeric PDGF isoforms), PDGF-,B receptor subunits preferentially bind PDGF-B chains (8, 13, 14) . Furthermore, occupancy of PDGF-,B receptor subunits is consistent with maximal cellular responsiveness (10, 11, (13) (14) (15) .
The present studies demonstrate that in osteoblastenriched cultures from fetal rat bone, the modest mitogenic effect ofPDGF-AA, by comparison to other PDGF isoforms, is enhanced by preexposure to IL-1 a or TNF-a. This result coincides with a specific increase in PDGF-AA binding site capacity, independent of a change in PDGF-BB binding. Increased PDGF-AA binding is not completely accounted for by the moderate effects of IL-la or TNF-a on cell replication (this report and reference 34), and does not seem nonspecific since, similar to results with murine 3T3 fibroblasts (45), TGF-# 1 specifically decreases PDGF-AA binding in the osteoblast-enriched cultures, and a variety of other agents are without effect in this regard.
Previous studies in the osteoblast-enriched cultures that are used in this report reveal a pattern of PDGF isoform cross-receptor binding in which PDGF-AA does not effectively compete for 1251I-PDGF-BB binding, while '251-PDGF-AA and 1251I PDGF-BB binding are each displaced by PDGF-BB (1 1). This result is consistent with other culture models (8, 13, 14) , and suggests that these cells express a conventional PDGF-a and PDGF-,B receptor recognition system. As seen previously in this and several other culture models, '25I-PDGF-BB-labeled complexes migrate on polyacrylamide gels at 185 kD (8, 18) . However, the relatively high migration ofthe predominant '25I-PDGF-AA-labeled complex found at > 200 kD in our unstimulated cultures suggests differences between the PDGF-AA binding sites on fetal rat osteoblasts and the 170-kD PDGF-AA-labeled complexes seen in human glioma and foreskin fibroblast-derived cultures (8, 12, 18) . The > 200-kD complexes have appeared consistently in our studies using four separate radiolabeled PDGF-AA preparations, two cross-linking reagents (DSS and BS3), and at DSS concentrations of 0.1-0.5 mM. Current attempts to characterize these fetal rat cell binding sites with anti-human PDGF receptor antibodies have not shown sufficient cross reactivity to resolve whether they are homologues of PDGF receptor subunits found in other culture models. Furthermore, the > 200-kD complexes may be particular only to certain tissues, or to cells at particular states ofdiffer- A recent report ofstudies performed with continuously cultured murine osteoblast-like cells (MC3T3-E1) also demonstrates that IL-la increases PDGF-AA effects, and suggests that this occurs by way of increased PDGF-a receptor subunit synthesis (48). However, in those studies, IL-1 a pretreatment increased both PDGF-AA and PDGF-BB activity to nearly the same extent, whereas only PDGF-AA activity and binding is enhanced in the fetal rat bone-derived cell culture model used in our studies. Nevertheless, the metabolic inhibitor studies that we report do not discount the possibility that continual or elevated PDGF-a receptor synthesis, as detected in MC3T3-EI cells, may be important for certain maximal biological responses, but they do indicate that the response to IL-la and TNF-a may be somewhat more complex than previously suspected. Alterations in PDGF-AA binding by the various treatments used in these studies also may be specific to certain tissues, or to cells from skeletal tissue at particular stages ofdevelopment, and different effects may be found in other cells or culture models. In this regard, our present results may only apply to osteoblasts within particular anatomical regions within bone, or may not be evident in bone tissue from some mature organisms or in fully differentiated osteoblasts.
Production of only PDGF-A ligand subunits by osteoblasts (6, 19) further indicates an important role for this isoform in the local control of bone cell activity. It is notable that three factors produced by activated macrophages (IL-l1a, TNF-a, and TGF-f3) share an ability to alter PDGF-AA, and not PDGF-BB binding in fetal bone cell cultures. This may indicate that other PDGF isoforms which are found in serum (3, 49) could be important in the systemic regulation of bone cell activity, but that specific and rapid changes at the local level may be restricted to PDGF-AA. An increase in osteoblast activity is noted histologically afterthe reversal phase ofbone remodeling, during which there is an appearance of macrophages (20) , and this may occur as a result of the interacting effects of macrophage-derived IL-la or TNF-a with osteoblast-derived PDGF-AA. Furthermore, macrophages accumulate within the area of inflammation after wounding (50) , and rapid increases in osteoblastic responses needed for fracture healing may be augmented by the synergistic activities between these agents and PDGF-AA, as observed in the present studies. Therefore, it appears that at least in some osteoblast populations, there is a highly developed mechanism for increasing PDGF-AA effectiveness, independent of an increase in ligand or receptor synthesis or release from binding proteins (as occurs with TGF-3 and the insulin-like growth factors). It is also notable that, unlike the stimulatory effects ofIL-la and TNF-a, TGF-# 1 specifically decreases PDGF-AA binding in this culture model, but that no biological response has yet been correlated with this effect. By itself, TGF-#3I is a strong biphasic mitogen in the osteoblast-enriched cell culture system used in these studies (25, 42, 43) . Consequently, its potency in this system makes it difficult to assess the interacting effects of TGF-f3l and the PDGFs using the pretreatment protocol developed for the present experiments.
In summary, the macrophage-derived factors IL-1 a and TNF-a specifically increase PDGF-AA binding and activity in osteoblast-enriched cultures from fetal rat bone. Although increased PDGF-AA binding occurs within complexes that seem normally to favor either PDGF-A or PDGF-B subunits in unstimulated cultures, there is a striking increase at 185 kD, which co-migrates with PDGF-BB binding complexes, consistent with the premise that binding within the 1 85-kD complex is necessary for maximal PDGF activity in bone cells (11) . These studies continue to implicate the fine balance that exists among multiple factors in the control ofbone cell activity, and suggest that cellular interactions, by way of specific local growth factors, may precisely regulate the complex processes of bone turnover and repair.
